NTLA Stock Rockets After Hours Before Critical Data For Genetic Disorder Therapy

• If data from a third-stage trial is supportive, the company expects to submit an application to the U.S. Food and Drug Administration (FDA) seeking approval for the therapy in the second half of 2026. 
• The company will announce the data on Monday. 
• In addition to lonvoguran ziclumeran, Intellia is also developing another therapy called Nexiguran Ziclumeran (Nex-z) for Transthyretin (ATTR) Amyloidosis.

Shares of Intellia Therapeutics (NTLA) jumped 22% after hours on Friday after the company said that it will announce clinical data from the late-stage trial of its experimental therapy lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE) on Monday.

Lonvo-z is designed to inactivate a gene in the liver, dramatically reducing or eliminating HAE attacks via a one-time treatment. Hereditary angioedema (HAE) is a rare, autosomal dominant genetic disorder causing recurrent, severe, non-itchy swelling in the limbs, face, intestinal tract, and airway.

Intellia completed enrollment of 80 patients in the global study in September 2025, ahead of schedule. If data from the trial is supportive, the company expects to submit an application to the U.S. FDA seeking approval for the therapy in the second half of 2026, with a launch planned for the first half of 2027.

In addition to lonvoguran ziclumeran, Intellia is also developing another therapy called Nexiguran Ziclumeran (Nex-z) for Transthyretin (ATTR) Amyloidosis. The U.S. Food and Drug Administration imposed a clinical hold on the company’s clinical trials in October after a patient experienced severe liver complications and subsequently died, but lifted the hold earlier this year, allowing the trials to proceed.

How Did Retail Traders React?

On Stocktwits, retail sentiment around NTLA stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.  

A Stocktwits user highlighted that the data announcement is coming earlier than expected and wondered if the move signals confidence. In February, the company had pitched the data announcement for mid-2026. 

https://www.stocktwits.com/Monkey7779192/message/651352863

Another user warned caution in light of the stock surge.

A third user said that they have “a good feeling” about the upcoming readout.

NTLA stock has gained 67% over the past 12 months. 

Read More: IHRT Stock Soars On Merger Talks With Sirius XM: Report

For updates and corrections, email newsroom[at]stocktwits[dot]com.